Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46617, USA.
Mike and Josie Harper Cancer Research Institute, South Bend, IN 46617, USA.
Int J Mol Sci. 2020 Oct 22;21(21):7844. doi: 10.3390/ijms21217844.
Resistance to chemotherapy occurs through mechanisms within the epithelial tumor cells or through interactions with components of the tumor microenvironment (TME). Chemoresistance and the development of recurrent tumors are two of the leading factors of cancer-related deaths. The Adenomatous Polyposis Coli (APC) tumor suppressor is lost in many different cancers, including colorectal, breast, and prostate cancer, and its loss correlates with a decreased overall survival in cancer patients. While APC is commonly known for its role as a negative regulator of the WNT pathway, APC has numerous binding partners and functional roles. Through APC's interactions with DNA repair proteins, DNA replication proteins, tubulin, and other components, recent evidence has shown that APC regulates the chemotherapy response in cancer cells. In this review article, we provide an overview of some of the cellular processes in which APC participates and how they impact chemoresistance through both epithelial- and TME-derived mechanisms.
化疗耐药性的产生是通过上皮肿瘤细胞内的机制,或通过与肿瘤微环境 (TME) 成分的相互作用而产生的。化疗耐药性和复发性肿瘤的发展是癌症相关死亡的两个主要因素。腺瘤性结肠息肉病 (APC) 肿瘤抑制因子在多种不同的癌症中丢失,包括结直肠癌、乳腺癌和前列腺癌,其缺失与癌症患者的总生存率降低相关。尽管 APC 通常因其作为 WNT 通路负调节剂的作用而闻名,但 APC 有许多结合伙伴和功能作用。通过 APC 与 DNA 修复蛋白、DNA 复制蛋白、微管蛋白和其他成分的相互作用,最近的证据表明 APC 调节癌细胞对化疗的反应。在这篇综述文章中,我们概述了 APC 参与的一些细胞过程,以及它们如何通过上皮和 TME 衍生的机制影响化疗耐药性。